McDonald K. Horne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
McDonald K. Horne has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Paula K. Merryman
6 shared publicationsAnn M. Cullinane
5 shared publicationsAnn Cullinane
2 shared publicationsDonna Jo McCloskey
Departments of Laboratory Medicine, W. G. Magnuson Clinical Center, Bethesda, Maryland
2 shared publicationsMargaret E. Rick
Department of Laboratory Medicine, W.G. Magnuson Clinical Center, Bethesda, MD, USA
2 shared publicationsRachna Vanjani
Hematology Service, Department of Laboratory Medicine, W. G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
2 shared publications
Latest Publications
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (5) , 773-778
Enhanced fibrinolysis in fingerstick blood samples: A possible role for matrix metalloproteinase-9
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (5) , 773-778
Enhanced fibrinolysis in fingerstick blood samples: A possible role for matrix metalloproteinase-9
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (4) , 517-521
Activation of blood coagulation in patients with major depressive disorder during euglycemic hyperinsulinemia
- 31 December 2007
- Published by Elsevier in Thrombosis Research
- Vol. 120 (4) , 517-521
Activation of blood coagulation in patients with major depressive disorder during euglycemic hyperinsulinemia
- 6 August 2007
- Published by Wiley in American Journal of Hematology
- Vol. 82 (9) , 815-820
The impact of major surgery on blood coagulation factors and thrombin generation
We studied the blood coagulation system of 14 patients with metastatic malignancies before and after they had undergone major surgery. In addition to measuring a battery of coagulation factors, we assessed the function of the system with assays of whole blood thrombin generation. With the exceptions of factor VIII (fVIII), which increased, and fibrinogen and fIX, which did not change, the activities of all the pro‐ and anticoagulant proteins were significantly lower postoperatively. However, the thrombin generating capacity of the system was relatively preserved. Although the integral of thrombin activity over time was lower after surgery, the mean peak thrombin concentration was unchanged and the time to clot formation was shortened. Similar changes could be reproduced by lowering the concentrations of pro‐ and anticoagulant factors together in control blood samples. Therefore, simultaneous reductions in pro‐ and anticoagulant proteins postoperatively worked to maintain the functional integrity of the blood coagulation system. Am. J. Hematol., 2007. Published 2007 Wiley‐Liss, Inc.
- 6 August 2007
- Published by Wiley in American Journal of Hematology
- Vol. 82 (9) , 815-820
The impact of major surgery on blood coagulation factors and thrombin generation
We studied the blood coagulation system of 14 patients with metastatic malignancies before and after they had undergone major surgery. In addition to measuring a battery of coagulation factors, we assessed the function of the system with assays of whole blood thrombin generation. With the exceptions of factor VIII (fVIII), which increased, and fibrinogen and fIX, which did not change, the activities of all the pro‐ and anticoagulant proteins were significantly lower postoperatively. However, the thrombin generating capacity of the system was relatively preserved. Although the integral of thrombin activity over time was lower after surgery, the mean peak thrombin concentration was unchanged and the time to clot formation was shortened. Similar changes could be reproduced by lowering the concentrations of pro‐ and anticoagulant factors together in control blood samples. Therefore, simultaneous reductions in pro‐ and anticoagulant proteins postoperatively worked to maintain the functional integrity of the blood coagulation system. Am. J. Hematol., 2007. Published 2007 Wiley‐Liss, Inc.
- Open Access
- 1 November 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (11) , 2107-2114
Markedly Increased Vitamin B12 Concentrations Attributable to IgG–IgM–Vitamin B12 Immune Complexes
Background: High serum vitamin B12 concentrations have been reported in patients with hepatic disease, disseminated neoplasia, myeloproliferative disorders, and hypereosinophilic syndromes. We recently discovered an extraordinarily increased vitamin B12 concentration in a patient without these underlying conditions.
- 1 November 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (11) , 2107-2114
Open AccessMarkedly Increased Vitamin B12 Concentrations Attributable to IgG–IgM–Vitamin B12 Immune Complexes
Background: High serum vitamin B12 concentrations have been reported in patients with hepatic disease, disseminated neoplasia, myeloproliferative disorders, and hypereosinophilic syndromes. We recently discovered an extraordinarily increased vitamin B12 concentration in a patient without these underlying conditions.
- 28 September 2006
- Published by Wiley in European Journal of Haematology
- Vol. 77 (6) , 533-537
Venlafaxine‐induced ecchymoses and impaired platelet aggregation
Objective: To describe a case of venlafaxine‐induced ecchymoses. Methods: A patient with a history of ecchymoses coincident with venlafaxine therapy was rechallenged with the drug. Her platelet function was assessed with aggregation and ATP release studies before the rechallenge and after she developed ecchymoses. In addition, the effect of venlafaxine on platelet aggregation and ATP release was studied in vitro by adding the drug to platelet‐rich plasma from normal donors. Results: After 4 wk of treatment with venlafaxine our patient developed extensive ecchymoses. At that time her platelet aggregation and release responses to epinephrine, ADP, collagen, and arachidonic acid were markedly suppressed. Adding venlafaxine to normal platelet‐rich plasma also dramatically reduced the aggregation and release responses to the same agonists as well as to serotonin, but the concentrations of venlafaxine required were 1000‐fold greater than those normally achieved clinically. Conclusions: Our patient demonstrated an idiosyncratic hypersensitivity to the platelet inhibitory effects of venlafaxine. Because venlafaxine is an inhibitor of serotonin uptake by platelets and neurons, this mechanism may contribute to the impact of this drug on platelet function. However, our in vitro studies suggest that this hypothesis is inadequate to explain the observations completely.
- 28 September 2006
- Published by Wiley in European Journal of Haematology
- Vol. 77 (6) , 533-537
Venlafaxine‐induced ecchymoses and impaired platelet aggregation
Objective: To describe a case of venlafaxine‐induced ecchymoses. Methods: A patient with a history of ecchymoses coincident with venlafaxine therapy was rechallenged with the drug. Her platelet function was assessed with aggregation and ATP release studies before the rechallenge and after she developed ecchymoses. In addition, the effect of venlafaxine on platelet aggregation and ATP release was studied in vitro by adding the drug to platelet‐rich plasma from normal donors. Results: After 4 wk of treatment with venlafaxine our patient developed extensive ecchymoses. At that time her platelet aggregation and release responses to epinephrine, ADP, collagen, and arachidonic acid were markedly suppressed. Adding venlafaxine to normal platelet‐rich plasma also dramatically reduced the aggregation and release responses to the same agonists as well as to serotonin, but the concentrations of venlafaxine required were 1000‐fold greater than those normally achieved clinically. Conclusions: Our patient demonstrated an idiosyncratic hypersensitivity to the platelet inhibitory effects of venlafaxine. Because venlafaxine is an inhibitor of serotonin uptake by platelets and neurons, this mechanism may contribute to the impact of this drug on platelet function. However, our in vitro studies suggest that this hypothesis is inadequate to explain the observations completely.
- 1 September 2006
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (9) , 1262-1267
Use of Heparin versus Lepirudin Flushes to Prevent Withdrawal Occlusion of Central Venous Access Devices
Study Objective. To determine whether lepirudin flushes are more effective than heparinized saline in preventing withdrawal occlusion of central venous access devices.Design. Randomized, double‐blind clinical trial.Setting. Research institution‐tertiary referral center.Patients. Forty‐nine adults undergoing bone marrow transplantation for hematologic malignancies or metastatic solid tumors.Intervention. Twenty‐four patients received heparin and 25 received lepirudin flushes. The heparin dose was 3 ml of porcine heparin 100 U/ml (300 U) per catheter lumen at least once/day; the lepirudin dose was 3 ml of lepirudin 100 μg/ml (300 μg) per catheter lumen at least once/day After 3–4 weeks, all 49 patients received the heparin flushes.Measurements and Main Results. Efficacy was assessed by the frequency with which the patients were treated with alteplase instillations for withdrawal occlusion of their central venous access devices during the first 4 months of catheterization. Three (12.5%) patients treated with heparin alone and five (20%) treated initially with lepirudin required alteplase instillations for an estimated relative risk with lepirudin versus heparin of 1.6 (95% confidence interval [CI] 0.40–13.86, p=0.70).Conclusion. Lepirudin was not more effective than heparin, which may have been related to the conservative dose of lepirudin administered. However, higher lepirudin doses are likely to incur an unacceptable risk of systemic anticoagulation.
- 1 September 2006
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (9) , 1262-1267
Use of Heparin versus Lepirudin Flushes to Prevent Withdrawal Occlusion of Central Venous Access Devices
Study Objective. To determine whether lepirudin flushes are more effective than heparinized saline in preventing withdrawal occlusion of central venous access devices.Design. Randomized, double‐blind clinical trial.Setting. Research institution‐tertiary referral center.Patients. Forty‐nine adults undergoing bone marrow transplantation for hematologic malignancies or metastatic solid tumors.Intervention. Twenty‐four patients received heparin and 25 received lepirudin flushes. The heparin dose was 3 ml of porcine heparin 100 U/ml (300 U) per catheter lumen at least once/day; the lepirudin dose was 3 ml of lepirudin 100 μg/ml (300 μg) per catheter lumen at least once/day After 3–4 weeks, all 49 patients received the heparin flushes.Measurements and Main Results. Efficacy was assessed by the frequency with which the patients were treated with alteplase instillations for withdrawal occlusion of their central venous access devices during the first 4 months of catheterization. Three (12.5%) patients treated with heparin alone and five (20%) treated initially with lepirudin required alteplase instillations for an estimated relative risk with lepirudin versus heparin of 1.6 (95% confidence interval [CI] 0.40–13.86, p=0.70).Conclusion. Lepirudin was not more effective than heparin, which may have been related to the conservative dose of lepirudin administered. However, higher lepirudin doses are likely to incur an unacceptable risk of systemic anticoagulation.
- Open Access
- 11 April 2006
- Published by Wiley in British Journal of Haematology
- Vol. 133 (4) , 403-408
The effect of red blood cells on thrombin generation
Summary: We have developed an assay of thrombin generation in clotting whole blood. Because our goal was to study patients with red blood cell diseases that are associated with thrombosis, the initial evaluation of this assay analysed the effect of the haematocrit and haemolysate on the total amount of thrombin activity generated and the maximal concentration of thrombin achieved. Both of these parameters were proportional to the haematocrit throughout a wide range of clinically relevant cell concentrations. Red cell lysate also augmented thrombin generation. Because this effect was removed by filtration of the lysate, we propose that it was related to red cell microparticles.
- 11 April 2006
- Published by Wiley in British Journal of Haematology
- Vol. 133 (4) , 403-408
Open AccessThe effect of red blood cells on thrombin generation
Summary: We have developed an assay of thrombin generation in clotting whole blood. Because our goal was to study patients with red blood cell diseases that are associated with thrombosis, the initial evaluation of this assay analysed the effect of the haematocrit and haemolysate on the total amount of thrombin activity generated and the maximal concentration of thrombin achieved. Both of these parameters were proportional to the haematocrit throughout a wide range of clinically relevant cell concentrations. Red cell lysate also augmented thrombin generation. Because this effect was removed by filtration of the lysate, we propose that it was related to red cell microparticles.
- 31 December 2005
- Published by Elsevier in Thrombosis Research
- Vol. 116 (6) , 499-507
Plasminogen interaction with platelets: The importance of carboxyterminal lysines
- 31 December 2005
- Published by Elsevier in Thrombosis Research
- Vol. 116 (6) , 499-507
Plasminogen interaction with platelets: The importance of carboxyterminal lysines
- 31 December 2005
- Published by Elsevier in Thrombosis Research
- Vol. 117 (1-2) , 15-17
Overview of hemostasis and thrombosis; current status of antithrombotic therapies
- 31 December 2005
- Published by Elsevier in Thrombosis Research
- Vol. 117 (1-2) , 15-17
Overview of hemostasis and thrombosis; current status of antithrombotic therapies
- 1 January 2005
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 94 (11) , 1108-1109
Clinical significance of hypodysfibrinogenemia γ 326 Cys -> Tyr?
- 1 January 2005
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 94 (11) , 1108-1109
Clinical significance of hypodysfibrinogenemia γ 326 Cys -> Tyr?